Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Development of drugs for Epstein-Barr virus using high-throughput in silico virtual screening.

Authors
  • Li, Ning
  • Thompson, Scott
  • Jiang, Hualiang
  • Lieberman, Paul M
  • Luo, Cheng
Type
Published Article
Journal
Expert Opinion on Drug Discovery
Publisher
Informa UK (Taylor & Francis)
Publication Date
Dec 01, 2010
Volume
5
Issue
12
Pages
1189–1203
Identifiers
DOI: 10.1517/17460441.2010.524640
PMID: 22822721
Source
Medline
License
Unknown

Abstract

Despite the impressive efficacy of nucleoside analogs for the treatment of herpesvirus lytic infection, there remain few effective treatments for latent infections. As EBV latent infection persists within and contributes to the formation of EBV-associated cancers, targeting EBV latent proteins is an unmet medical need. High-throughput in silico screening can accelerate the process of drug discovery for novel and selective agents that inhibit EBV latent infection and associated disease.

Report this publication

Statistics

Seen <100 times